Androgen Deprivation Therapy for Prostate Cancer
Pp. 134-171 (38)
Patricia Tai, Evgeny Sadikov, Asim Amjad, Nelson Leong, Arbind Dubey, Wojciech Dolata, Miroslav Jancewicz and Rashmi Koul
In the past, androgen deprivation therapy (ADT) was used for the
conservative treatment of prostatic cancer, but now also used in the setting of
neoadjuvant and adjuvant treatment in combination with radiotherapy. Another use is
for loco-regional or distant recurrence after primary treatment of surgery or
radiotherapy. ADT is an alternative for local failure after radical treatment and it
compares favorably with cryotherapy or high-intensity focused ultrasound therapy.
Traditionally gonadotropin releasing hormone (GnRH) agonists are used. A new class
of agent in clinical use is the gonadotrophin antagonist degarelix. Newer choices for
castrate resistant prostate cancer include abiraterone and enzalutamide. The emphasis
of this review is on drug discovery, design and clinical trials. The indication and
rationale for choosing the appropriate first and second line drugs will be discussed for
easy access at point of care. This chapter summarizes the recent developments and the
controversies to be explored in the future which will be of interest to all health care
professionals, colleagues in the pharmaceutical industry, family physicians, urologists,
radiation and medical oncologists. We also add our clinical experience of use of
different ADT throughout this review to make it practical for bedside management.
Common questions from physicians and patients are answered in this review.
Androgen deprivation therapy, Anti-androgens, Agonist, Antagonist,
Adjuvant, Biochemical failure, Clinical trials, Degarelix, Gonadotropin-releasing
hormone, Metastasis, Prostate cancer, Prostate-specific antigen, Primary
Departments of Radiation Oncology.